Latest Options News

Enlitic, Inc. has launched a A$10 million placement alongside an offer of 125 million unquoted options, aiming to fuel growth in its AI-driven healthcare technology business. The move underscores both funding ambitions and the complex risks tied to AI adoption and market dynamics.

Cobre Limited has announced a fully underwritten loyalty options offer to raise approximately $1.18 million, offering eligible shareholders one new option for every three shares held at $0.008 each. The new options carry an exercise price of $0.066 and expire in November 2028.

Cobre Limited has secured $500,000 through a placement and is now launching a fully underwritten Loyalty Options Rights Issue to raise approximately AU$1.18 million, supporting its capital-light, catalyst-rich copper exploration strategy in Botswana.

Clarity Pharmaceuticals’ novel PET imaging agent Cu-SAR-Bombesin demonstrated safety and effectiveness in detecting prostate cancer recurrence missed by standard scans in its Phase II SABRE trial. The agent identified lesions in about one-third of patients with negative or equivocal standard imaging.

Invion Limited launches a Loyalty Option entitlement offer aimed at raising up to $16 million to support its advancing cancer clinical trials, including a promising anogenital cancer study with Peter MacCallum Cancer Centre.

Thrive Tribe Technologies has announced a proposed 20, 1 share consolidation aimed at streamlining its capital structure, pending shareholder approval at the upcoming Extraordinary General Meeting.

AdAlta Limited has successfully placed the remaining shortfall in its renounceable rights issue, raising a total of $1.3 million to advance its cellular immunotherapy pipeline. The company also addressed an administrative breach involving director share allocations, ensuring compliance with ASX rules.

Macarthur Minerals has relaunched a renounceable rights issue to raise nearly A$2 million, fully underwritten by Gold Valley, aiming to fund its Lake Giles Iron Project and strengthen its balance sheet.

Macarthur Minerals Limited has issued a replacement prospectus for a renounceable entitlement offer aiming to raise approximately AUD 2 million, fully underwritten by Gold Valley Yilgarn Pty Ltd. The offer includes free attaching options and supports the company’s exploration and operational funding needs.

Dimerix has reached a key milestone by dosing 200 adult patients in its Phase 3 ACTION3 trial for FSGS, progressing steadily toward full recruitment expected in late 2025.

Newmont Corporation has updated its dividend announcement to clarify currency exchange rates and payment options for its upcoming Q1 2025 dividend, highlighting tax and payment logistics for investors.

Syntara Limited reports encouraging interim Phase 2 data for its drug SNT-5505 combined with ruxolitinib, demonstrating significant symptom relief and spleen volume reduction in myelofibrosis patients. The company plans to engage the FDA soon to discuss pivotal trial design.